Aspen Neuroscience’s sasineprocel starts with cells collected from a patient’s skin and aims to rebuild a population of neurons lost in Parkinson’s disease. To advance clinical testing, the company has raised $140.6 million through an initial public offering. The program now has to answer a central
Injectable amniotic membrane powder is being investigated for its disease-modifying potential in treating osteoarthritis, as it contains factors that suppress enzymes responsible for cartilage breakdown. This transition from a specialized tool in ophthalmology to a cornerstone of orthopedics and
Addressing the chronic ischemia found in diabetic ulcers requires the upregulation of vascular endothelial growth factor, a process achievable through ultrasound-microbubble therapy. The skin functions as a highly sophisticated, multi-layered organ that maintains a constant state of flux, balancing
The partnership between clinical leaders at Harvard and manufacturing experts at Landmark Bio aims to bridge the gap between laboratory breakthroughs and clinical-grade therapies. For infants born with complex congenital heart defects, the current medical standard often involves a harrowing series
Engineering a synthetic alternative to natural nerve grafts requires a complex balance of structural durability, nutrient diffusion, and precise biological signaling. When peripheral nerves are severed, the internal fibers often lose their way, leading to permanent loss of sensation and motor
Root canal therapy effectively prevents the spread of infection but strips a tooth of its sensory integrity and its ability to respond to future biological stress. For decades, the primary clinical paradigm has been centered on the replacement of organic loss with inorganic materials, a process
